BE-PEP Rifampicin
Phase 3Small molecule
BE-PEP Rifampicin is one of 8 small molecule programs targeting Leprosy. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
8 competitors in Leprosy
#DrugCompanyPhaseTrials
1Rifadin
SanofiApproved
Lamprene
NovartisApproved
Neoral
NovartisApproved
Avlosulfon
AAlmirall, S.A.
Approved
Glucophage
EMD SeronoPhase 2
BE-PEP Rifampicin
IInstitute of Tropical Medicine, Belgium
Phase 3
Acetylcholine Iontophoresis
JJames J. Peters Veterans Affairs Medical Center
Preclinical
Clofazamine
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BE-PEP Rifampicin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details